ReviewInfectious diseases and therapy2026
The Future of Antibiotics and Artificial Intelligence: Some Thoughts from Discovery to Bedside.
Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Next-Generation Strategies to Encounter Antimicrobial Resistance (AMR): From Lariocidin to Gene Editing and Nanotechnology-Based Approaches.Molecules (Basel, Switzerland) · 2026Review
- Artificial Intelligence in Infectious Disease Care: Selected Applications in Tuberculosis, Sepsis, and Antimicrobial Stewardship.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- A Theoretical Framework forInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic discovery and antibiotic prescribing represent two domains that both stand to benefit from artificial intelligence (AI)-driven progress in the near future. In this article, we discuss these parallel advances and the potential future synergy between AI-enabled antibiotic discovery and AI-assisted antibiotic prescribing. Although multiple challenges remain before these two domains meaningfully converge, their integration could amplify the strengths of each: discovery pipelines generating broader, more diverse classes of antibacterial agents, and prescribing tools capable of matching these agents to individual patients with unprecedented precision. Such a scenario could transform antibiotic therapy by enabling AI-supported, patient-specific treatment decisions while reinforcing the principles of precision medicine and antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.